A brief review of preclinical and clinical studies with LY171883 and some comments on newer cysteinyl leukotriene receptor antagonists.
Fleisch
J H
JH
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
Cloud
M L
ML
Marshall
W S
WS
D000098:Acetophenones / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D001393:Azoles / Q000494:pharmacology*; D001980:Bronchi / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology; D003998:Dicarboxylic Acids / Q000494:pharmacology; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D000882:Haplorhini; D006801:Humans; D007191:Indazoles / Q000494:pharmacology; D017999:Leukotriene E4; D018077:Receptors, Leukotriene; D011982:Receptors, Prostaglandin / Q000187:drug effects*; D013189:SRS-A / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use
D000098:Acetophenones; D001393:Azoles; D002867:Chromones; D003998:Dicarboxylic Acids; D007191:Indazoles; D018077:Receptors, Leukotriene; D011982:Receptors, Prostaglandin; D013189:SRS-A; D013777:Tetrazoles; C054217:ICI 198615; D017999:Leukotriene E4; C044660:LY 171883; C006312:FPL 55712; C049043:LY 163443; C052027:SC 39070; C052393:pobilukast; C047681:pranlukast